Based on data from a 1994 survey, 1 in 17 Americans are bilaterally and 1 in 15 unilaterally already having cataract. A survey in 1997 found 1 in 13 Americans had had cataracts at that point; this number has increased to somewhere between 1 in 9 and 1 in 13 in recent years.
The following table presents the treatments most commonly used to treat the diseases of lens.\nPossible solutions to treatment are surgery for [cataract](https://www.withpower.com/clinical-trials/cataract) and medications to treat glaucoma, corneal abrasions, and uveitis.\n\nThe treatment for cancer depends on the cancer type. For breast cancer, surgery may be combined with radiotherapy or chemotherapy in adjuvant therapy. Often hormone therapy is combined with adjuvant treatment. Lung cancer may respond to a combination of surgery, chemotherapy, or targeted therapy. For prostate cancer, surgery is often used in combination with radiation or hormonal therapy. For skin cancers, surgery or chemotherapy are common treatments.
A large number of people in this country still have un-corrected cataract and thus would benefit from getting their eyes assessed. In India surgical correction of cataract is not cost effective and this should be a part of National Vision Programme, as already in USA.
Early signs of cataract include blurred/blurry vision, eye redness/pain, and seeing haloes of light when viewing near objects. Lid sagging is the most common and visually disruptive sign of cataract, while haloes of light become progressively more frequent and are most noticeable when attempting to see far objects. The presence of these signs can contribute to the development of cataract. In patients who develop signs of cataract, the vision remains stable or worsens within five years.\n
Cataract is a multifactorial disease whose cause may include genetics, immune modulation by a variety of factors, environmental factors, ageing-related alterations to the eye and retina. Some of this may also originate in the fetus.
There was no discovery of any kind in the area of cataract. One major problem is finding a lens that can be implanted in the eye without causing too many complications. I still think that a lens that is made from silicone but with an integrated, polymethyl methacrylate design for its anterior is really a useful idea. Other than these, there has been no good research on how to prevent cataract. One way is to look for a disease that is linked to cataract. One disease that has been suggested is diabetes which causes corneal clouding and glaucoma. When both are present it can cause cataract. But even in those diseases, how to treat is not clear.
light adjustable lens (lal) is safe. In lald patients, LD is safe for people who are not willing to undergo LD. In lald patients, LD is helpful for reducing cataract-induced glare.
Light adjustable lens for therapeutic lens use has still some limitations and a lot more improvements are made to the currently available devices. LDD's have emerged as a more convenient way to use light for therapy.
There are currently no clinical trials on the use of light, adjusting lens and light delivery device for post-surgical treatment of glaucoma. There were also no randomized controlled trials. Hence, no conclusions can be drawn concerning this technology. It must be kept in mind in the context of current state of knowledge of the treatment of glaucoma, that this technology is only suggested, but not yet approved. —- The treatment will not cure or prevent glaucoma. Moreover, it is only used for post-surgical treatment and does not replace medications used for glaucoma treatment. —- There are no studies demonstrating improvement in central ACD (central axis).
Both are equally effective in alleviating glare. The adjustable lens does not decrease accommodation for more than a night but the LD (or both) can significantly reduce accommodation in the day and for longer periods. The LD also has the advantage of lowering glare on the whole of vision even during the day and also of reducing glare when worn in the daytime.
Clinical trials are only an option for patients who are likely to benefit from their treatment. The patient with high personal and/or economic need should be the main target for any future clinical trials to be conducted. The researchers in this study must consider the interests of these patients.